JPIAMR is launching an international call for projects under the umbrella of the JPIAMR and within the framework of the ERA-NET JPIAMR-ACTION. The call Disrupting drug resistance using innovative design involves 27 funding organisations from 18 countries. The total estimated call budget is close to 19 million Euro.
This call is closed.
In line with the JPIAMR Strategic Research and Innovation Agenda, this call will focus on tackling the rising threat of antimicrobial resistance. Declining effectiveness of existing antimicrobials together with the low and insufficient number of promising new antimicrobials in the pipeline stresses the urgency to develop new protocols and innovative approaches for effective delivery and use of the already existing antimicrobials. This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.
Through this call, the ERA-NET JPIAMR-ACTION intends to create and reinforce the collaboration between research partners coming from different countries and different fields of expertise to promote research on antimicrobial resistance.
Topic of the call
Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:
- Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
- Drug/plant protection agent repurposing;
- Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
- Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
- Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.
Proposals can focus on one or more of the three “One-Health” settings, namely:
- Human Health, and/or
- Animal Health (including wildlife, livestock, fishes, and companion animals), and/or
- Plants (including trees and crops)
The following sub-topics are out of scope of the call:
- Antiviral and antiparasitic agents
- Discovery and/or screening of new compounds, new vaccines and/or new targets
- Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)
Participation of end-users, stakeholders and companies is encouraged.
Consortia should consists of a maximum of six (6) project partners (including non-funded partners). The maximum number of partners can be increased to seven (7) if the consortium includes a company, or a partner coming from low or middle income countries, Lithuania or Poland. The budget of non-funded partners shall not exceed 30% of the total transnational project budget requested. Furthermore, consortia should always consist of a majority of project partners eligible for funding. Funding is granted for a maximum of three (3) years in accordance with national regulations and applicable legal provisions.
The call Disrupting drug resistance using innovative design will follow a two-step evaluation procedure.
11 January 2022 (10.00 CET) – Call opens
8 March 2022 (14.00 CET) – Deadline pre-proposals
5 July 2022 – Deadline full proposals
Please contact the call secretariat if you have any questions about the call: JPI-AMRCalls@agencerecherche.fr
Information & application
- Call text (pdf 1 MB) Updated 2022-01-28: Changes in Annex B (National Rules and Requirements) for the United Kingdom. All specific information on the call “Disrupting drug resistance using innovative design”.
- Pre-proposal application form (Word file 0,1 MB). Updated 2022-02-10: Modifications of the table in section B3 and the letter of intent in Annex C. The application form must be attached to the application in the submission platform.
- Submission platform. The pre-proposal must be submitted by the coordinator before 8 March 2022, 14h CET using the electronic submission platform.
- Applicants from LMIC countries (for more details see Call text, Annex B: National Rules and Requirements):
- Sida will support participation of researchers from low income countries in sub-Saharan Africa, and other sub-Saharan African countries where Sweden has bilateral development cooperation. General Conditions applicable to Grants from Sida to NGO:s, regarding project/programme support and core support (pdf 0,15 MB)
Webinar for applicants
A live webinar for applicants was held on the 25th of January 2022 presenting the call and the partner search tool. Representatives from funders participating in the call were available to answer questions.
The webinar was recorded and the videos are now available on the JPIAMR YouTube channel:
Questions and Answers:
- Selection the Q&As from the webinar (pdf 0,1 MB)
Partner Search Tool
A match-making tool has been created for applicants, to facilitate networking and the creation of consortia.
The tool can be consulted for several purposes:
- Partner looking for project: As individual researcher or a representative of a lab or research team, searching for a project to join.
- Project looking for partner: If you want to build a consortium around an existing project and want to find partners for your project ideas.
Partner Search Tool for the call Disrupting drug resistance using innovative design
Partners working in eligible low and middle income countries can be funded by the Swedish International Development Cooperation Agency (Sida).
Fonds voor Wetenschappelijk onderzoek-Vlaanderen (FWO)
Fonds de la Recherche Scientifique (FNRS)
Canadian Institute of Health Research (CIHR)
Ministry of Education, Youth and Sports (MEYS)
Innovation Fund Denmark (IFD)
Estonian Research Council (ETAg)
Agence Nationale de la Recherche (ANR)
The Federal Ministry of Education and Research (BMBF)
National Research, Development and Innovation Office (NKFIH)
Ministry of Health (CSO-MOH)
Fondazione Regionale per la Ricerca Biomedica (FRRB)
Ministero della Salute (It-MoH)
Valsts Izglitibas Attistibas Agentura (VIAA)
Latvijas Zinatnes padome (LZP)
Research Council of Lithuania (RCL)
Agentia Nationala Pentru Cercetare Si Dezvoltare (ANCD)
Narodowe Centrum Nauki (NCN)
National Centre for Research and Development (NCBR)
Agencia Estatal de Investgacion (AEI)
Instituto de Salud Carlos III (ISCIII)
Swedish Research Council (SRC)
Swedish International Development Cooperation Agency (Sida)
Vinnova, Sweden’s innovation agency
Swiss National Science Foundation (SNSF)
Medical Research Council (MRC)
Biotechnology and Biological Sciences Research Council (BBSRC)
Engineering and Physical Sciences Research Council (EPSRC)
Thirteen projects involving 72 partners from 15 different countries have been recommended for funding within the JPIAMR 14th transnational call: “Disrupting drug Resistance Using Innovative Design” The total funding amount is 15,4 M€. Click on the project titles in the list below to learn more on each project.
- Development and in vivo validation of a novel triggered release antibiofilm coating for orthopaedic implants and vascular grafts. (TRA-COAT)
- Optimization and implementation of ceftazidime or ceftazidime-avibactam combined with fosfomycin against highly resistant gram-negative bacteria (CAVIFOS)
- Optimisation of bi-therapy inhibition of Staphylococcus aureus in persistent and bacteremic infections (StopStaphGrowth)
- The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin (MURYXIN)
- Identification of a Novel non-antibiotic Bactericidal agent to fight antimicrobial resistance (NOBACT)
- Targeted Nitroxoline Delivery for Treatment of Multidrug-resistant Pathogens (TANDEM)
- Disrupting drug resistance by exploiting collateral sensitivity to design novel therapeutic strategies for C. auris and C. glabrata (CycleDrug)
- Design and implementation of silver-based nanoparticles for combating antibiotic resistance (VARIANT)
- Optimization of Antibiotic Combinations using Organoids for treatment of Mycobacterium abscessus infections (ACOMa)
- New Inhalation Formulations for Improved Delivery of Antimicrobials (APRINHA)
- LyophilizeD fecal micrObiome traNsfer for primAry closTridioides difficilE infection (DONATE study): a multicenter randomized controlled trial (DONATE)
- Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine (SulTAn)
- Design and implementation of effective cOmbination of Phages and Antibiotics for improved TheRApy protocols against KLEbsiella pneumoniae (KLEOPATRA)